Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Technical Insights Tutorial

Bell Direct
March 7, 2016

Daily Trading Idea Tutorial

Bell Direct
March 7, 2016

Market Insights 26 Feb

Julia Lee
February 26, 2016

Small Cap CEO Interview: Ahalife

Bell Direct
February 24, 2016

Bell Potter: Hybrid stocks

Bell Direct
January 28, 2016

Bell Potter outlook: resources

Bell Direct
January 26, 2016

Richard Hemming: small cap dividend stocks

Richard Hemming
January 22, 2016

Bell Potter Financials Outlook

Bell Direct
January 22, 2016

Travel Sector Outlook

Bell Direct
January 22, 2016